Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy

The aim of this study is to determine whether chemotherapy prior to tumor removal (neoadjuvant chemotherapy), in patients undergoing treatment for colon cancer in occlusion (CCO), would improve the rate of patients able to benefit from "optimal" treatment, i.e. complete treatment (including all neoadjuvant and adjuvant chemotherapy cures). This new strategy, which would combine chemotherapy before surgery and possibly post-operatively (depending on tumor analysis), could improve the prognosis of occluded colon cancers by treating circulating micrometastases and/or inducing a reduction in tumo

Trial Details

NCT ID
NCT06107920
Phase
PHASE3
Sponsor
University Hospital, Rouen
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Neoadjuvant chemotherapy
Locations (sample)
  • Amiens, France|49.9,2.3
  • Beauvais, France|49.43333,2.08333
  • Besançon, France|47.24878,6.01815
  • Bobigny, France|48.90982,2.45012
  • Caen, France|49.18585,-0.35912

Key Eligibility Criteria

  • Age ≥ 18 years
  • ECOG performance status 0 or 1
  • Patients with obstructive colon cancer treated by defunctioning stoma
  • Pathologically confirmed adenocarcinoma (≥10 cm from the anal verge- left transverse colon) - MSS/pMMR (microsatellites stable primary tumor) status

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →